ATE227297T1 - 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel - Google Patents

2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel

Info

Publication number
ATE227297T1
ATE227297T1 AT94917922T AT94917922T ATE227297T1 AT E227297 T1 ATE227297 T1 AT E227297T1 AT 94917922 T AT94917922 T AT 94917922T AT 94917922 T AT94917922 T AT 94917922T AT E227297 T1 ATE227297 T1 AT E227297T1
Authority
AT
Austria
Prior art keywords
complexes
derivatives
contrast agents
acid
polyazamacrocyclophosphonic
Prior art date
Application number
AT94917922T
Other languages
English (en)
Inventor
Garry E Kiefer
Won D Kim
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ATE227297T1 publication Critical patent/ATE227297T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/281—Means for the use of in vitro contrast agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT94917922T 1993-05-06 1994-05-05 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel ATE227297T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/057,588 US5462725A (en) 1993-05-06 1993-05-06 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
PCT/US1994/005009 WO1994026275A1 (en) 1993-05-06 1994-05-05 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents

Publications (1)

Publication Number Publication Date
ATE227297T1 true ATE227297T1 (de) 2002-11-15

Family

ID=22011534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917922T ATE227297T1 (de) 1993-05-06 1994-05-05 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel

Country Status (17)

Country Link
US (1) US5462725A (de)
EP (1) EP0711300B1 (de)
JP (1) JPH08510245A (de)
CN (1) CN1125905A (de)
AT (1) ATE227297T1 (de)
AU (1) AU678583B2 (de)
BG (1) BG100192A (de)
CA (1) CA2162174A1 (de)
CZ (1) CZ289595A3 (de)
DE (1) DE69431660T2 (de)
FI (1) FI955319A7 (de)
HU (1) HUT74565A (de)
LV (1) LV11430B (de)
NO (1) NO301829B1 (de)
PL (1) PL311643A1 (de)
SG (1) SG46458A1 (de)
WO (1) WO1994026275A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409689A (en) * 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
DE19523891C1 (de) * 1995-06-30 1996-11-21 Hoechst Ag Chirale Mangan-triazanonankomplexe und Verfahren zu ihrer Herstellung
KR20000010533A (ko) * 1996-04-19 2000-02-15 텍사스 테크 유니버시티 시각적 조직 특이성 조영제로서의 형광 킬레이트
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
EP1362861B1 (de) * 1999-09-13 2005-12-14 Bristol-Myers Squibb Pharma Company Makrocyclische Chelatbildner für Metallopharmazeutika
US6685914B1 (en) 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
CA2382057A1 (en) * 1999-09-13 2001-03-22 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
AU2002323528C1 (en) * 2001-09-04 2009-11-12 Texas Tech University Multi-use multimodal imaging chelates
US6962690B2 (en) 2001-10-22 2005-11-08 Dow Global Technologies Inc. Tissue specific fluorescent chelates possessing long wavelength UV excitation
WO2003098232A2 (en) * 2002-05-17 2003-11-27 Case Western Reserve University Chemical shift markers for improved wireless fiducial marker tracking
WO2006020779A2 (en) * 2004-08-10 2006-02-23 Dow Global Technologies Inc. Targeting chelants and chelates
EP1637524A1 (de) * 2004-09-20 2006-03-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 10-substituierte 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecanederivate zur Verwendung als Kontrastmittel
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2581639C (en) * 2004-09-30 2016-07-26 Molecular Devices Corporation Luminescent lanthanide complexes
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
BRPI0806403A2 (pt) 2007-02-09 2011-09-06 Genentech Inc anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
US8499251B2 (en) 2009-01-07 2013-07-30 Microsoft Corporation Virtual page turn
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
PT2437785E (pt) 2009-06-04 2015-04-20 Novartis Ag Método de identificação de sítios para conjugação de igg
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
JP6324376B2 (ja) 2012-07-04 2018-05-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗テオフィリン抗体および使用方法
EP3089758B1 (de) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Kovalent verknüpfte helikar-/anti-helikar-antikörperkonjugate und verwendungen davon
EP3089759B1 (de) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Kovalent verknüpfte polypeptidtoxin-antikörperkonjugate
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
JP6618539B2 (ja) 2014-12-17 2019-12-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ソルターゼを使用した酵素媒介性のポリペプチドコンジュゲーションのための方法
EP3353201B1 (de) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Rekombinante schwere immunglobulinketten mit einer sortasekonjugationsschleife und konjugate davon
EP3353314A1 (de) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidierung mit sortase a in tiefeutektischen lösungsmitteln
JP6998862B2 (ja) 2015-09-25 2022-02-04 エフ.ホフマン-ラ ロシュ アーゲー 可溶性ソルターゼa
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ソルターゼaを利用してチオエステルを作製するための方法
CN109072212B (zh) 2016-03-30 2022-10-04 豪夫迈·罗氏有限公司 改善的分选酶
WO2018191389A1 (en) 2017-04-12 2018-10-18 Roche Sequencing Solutions, Inc. A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction
EP4707307A2 (de) 2017-07-13 2026-03-11 Roche Diagnostics GmbH Neues bindemittel und test für pivka
EP3697813A1 (de) 2017-10-20 2020-08-26 H. Hoffnabb-La Roche Ag Kopierschutz für antikörper
CN111918876B (zh) 2017-11-30 2024-02-02 豪夫迈·罗氏有限公司 抗pd-l1抗体及使用其检测pd-l1的方法
EP3492460A1 (de) * 2017-12-01 2019-06-05 Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. Verbindungen zur trennung von seltenerdelementen, trennverfahren und verwendung davon
WO2019175131A1 (en) 2018-03-14 2019-09-19 F. Hoffmann-La Roche Ag Method for affinity maturation of antibodies
WO2019175127A1 (en) 2018-03-14 2019-09-19 F. Hoffmann-La Roche Ag Novel anti-troponint antibodies
WO2019201901A1 (en) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Novel anti-thymidine kinase antibodies
CN112639475A (zh) 2018-08-31 2021-04-09 豪夫迈·罗氏有限公司 Dlbcl的预后指数中的胸苷激酶(tk-1)
CN116271117A (zh) 2018-09-28 2023-06-23 伊麦吉纳博公司 Cd8成像构建体及其使用方法
EP3747852B1 (de) 2019-06-05 2022-10-26 Ustav organicke chemie a biochemie AV CR, v.v.i. Verbindungen zur chromatografischen trennung von seltenerdelementen und s-, p-, d- metallen, verfahren zur trennung und verwendung davon
EP4004554A1 (de) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a9 als blutbiomarker zur nichtinvasiven diagnose von endometriose
JP2022542056A (ja) 2019-07-22 2022-09-29 エフ.ホフマン-ラ ロシュ アーゲー 子宮内膜症の非侵襲的診断のための血液バイオマーカーとしてのs100a6
WO2021013781A1 (en) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag Substance p as blood biomarker for the non-invasive diagnosis of endometriosis
EP4004553A1 (de) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a8 als blutbiomarker zur nichtinvasiven diagnose von endometriose
EP4004552A1 (de) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a12 als blutbiomarker zur nichtinvasiven diagnose von endometriose
BR112022002376A2 (pt) 2019-08-09 2022-04-26 Hoffmann La Roche Anticorpos que se ligam especificamente à troponina t cardíaca humana, anticorpos, moléculas de ácido nucleico, vetor, composição e método para determinar a troponina t cardíaca humana
JP7783809B2 (ja) 2019-11-15 2025-12-10 エフ. ホフマン-ラ ロシュ アーゲー 患者試料における質量分析測定のためのβ-ラクタム抗生物質の誘導体化
EP4237855A1 (de) 2020-10-30 2023-09-06 F. Hoffmann-La Roche AG Timp1 als marker für cholangiokarzinome
WO2022090455A1 (en) 2020-11-02 2022-05-05 F. Hoffmann-La Roche Ag Sars-cov-2 nucleocapsid antibodies
WO2022207628A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf as blood biomarker for the non-invasive diagnosis of endometriosis
WO2022207685A1 (en) 2021-04-01 2022-10-06 F. Hoffmann-La Roche Ag Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis
CN117337394A (zh) 2021-05-17 2024-01-02 豪夫迈·罗氏有限公司 sFRP4作为血液生物标志物用于子宫腺肌病的非侵入性诊断
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体
WO2023131594A1 (en) 2022-01-05 2023-07-13 F. Hoffmann-La Roche Ag Derivatization of compounds in patient samples for therapeutic drug monitoring (tdm)
WO2023247752A1 (en) 2022-06-23 2023-12-28 F. Hoffmann-La Roche Ag Method for diagnosing endometriosis and for classifying the stage of endometriosis
US20260036596A1 (en) 2022-07-22 2026-02-05 Roche Diagnostics Operations, Inc. Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
CN119585618A (zh) 2022-07-22 2025-03-07 豪夫迈·罗氏有限公司 成纤维细胞生长因子结合蛋白1(fgfbp1)作为(血液)生物标志物用于诊断多囊卵巢综合征
EP4558825A1 (de) 2022-07-22 2025-05-28 F. Hoffmann-La Roche AG Meteorin-ähnliches protein (metrnl) als (blut) biomarker zur diagnose des polyzystischen ovarialsyndroms
EP4565570A1 (de) * 2022-08-01 2025-06-11 Portland State University Kontraststoffe mit hoher relaxivität und stereoselektives präparat
WO2025026908A1 (en) 2023-07-28 2025-02-06 Roche Diagnostics Gmbh Serum epha1 as biomarker for endometriosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2609390A (en) * 1950-06-01 1952-09-02 Frederick C Bersworth Phosphonic alkylene polyamino acids and method of producing same
US3336221A (en) * 1964-11-05 1967-08-15 Calgon Corp Method of inhibiting precipitation and scale formation
US3331773A (en) * 1966-07-22 1967-07-18 Grace W R & Co Process for inhibiting precipitation in water
US3434969A (en) * 1967-08-11 1969-03-25 Calgon Corp Scale inhibiting
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
JP2831073B2 (ja) * 1988-06-24 1998-12-02 ザ ダウ ケミカル カンパニー 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
GB8914543D0 (en) * 1989-06-23 1989-08-09 Parker David Chemical compounds
US5247077A (en) * 1989-06-23 1993-09-21 Celltech Limited Tri-aza macrocycles and processes for their preparation
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
IL106159A0 (en) * 1992-06-30 1993-10-20 Dow Chemical Co Targeted delivery of growth factors for bone regeneration
EP0588229A3 (en) * 1992-09-12 1994-06-15 Hoechst Ag Macrocyclic chelating agents for the preparation of technetium or rhenium complexes

Also Published As

Publication number Publication date
AU6944794A (en) 1994-12-12
NO954440D0 (no) 1995-11-06
BG100192A (en) 1996-12-31
HUT74565A (en) 1997-01-28
US5462725A (en) 1995-10-31
LV11430A (lv) 1996-08-20
EP0711300A1 (de) 1996-05-15
CA2162174A1 (en) 1994-11-24
DE69431660T2 (de) 2003-08-21
EP0711300A4 (de) 1996-03-12
FI955319A0 (fi) 1995-11-06
AU678583B2 (en) 1997-06-05
JPH08510245A (ja) 1996-10-29
HU9503174D0 (en) 1996-01-29
SG46458A1 (en) 1998-02-20
CN1125905A (zh) 1996-07-03
PL311643A1 (en) 1996-03-04
CZ289595A3 (en) 1997-01-15
WO1994026275A1 (en) 1994-11-24
EP0711300B1 (de) 2002-11-06
DE69431660D1 (de) 2002-12-12
FI955319L (fi) 1995-12-22
NO954440L (no) 1996-01-05
NO301829B1 (no) 1997-12-15
FI955319A7 (fi) 1995-12-22
LV11430B (en) 1997-04-20

Similar Documents

Publication Publication Date Title
DE69431660D1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäuren, ihre komplexe und derivate zur verwendung als kontrastmittel
ATE316377T1 (de) Tricyclopolyazamacrocyclophosphonsäuren, ihre komplexe und derivate, für eine verwendung als kontrastmittel
ATE277058T1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
TR200103525T2 (tr) Bisiklik poliaminosit metal kompleksleri, bunları hazırlamak için yöntem ve bunların tıbbi görüntülemede kullanımı.
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
PL338339A1 (en) Novel derivatives of tetrazole
DE3766157D1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
AU8330898A (en) Substituted heterocycles and their use in medicaments
MY109602A (en) Heteroatoms-containing tricyclic compounds
DE69230970D1 (de) Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
DE69223504D1 (de) Bicycloazamakrocyclophosphon-Säure, Komplexe, Konjugate, Kontrastmittel und Herstellung
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
DE60008400D1 (de) Triazolopyrimidinderivate
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
ATE306283T1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
DE3673227D1 (de) 99mtc(iii)-agenzien zur myokardialen darstellung, in vivo nichtreduzierbar.
UA86379C2 (ru) Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties